Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAF312 in polymyositis and dermatomyositis
2008-006311-21Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyositis (PM) and dermatomyositis (DM) comparing BAF312 with Placebo (2 arms). Primary endpoint: IMACS Definition of Improvement responder status. Started Jun 2009; status: terminated.
02
Drugs
siponimod
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on 2008-006311-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006311-21.